InCarda Therapeutics raises $42M in Series B for inhaled cardiovascular drug
The San Francisco-based company plans to use the money primarily to fund its ongoing Phase II study of the drug, which it initiated in May.
Morningside Venture
The San Francisco-based company plans to use the money primarily to fund its ongoing Phase II study of the drug, which it initiated in May.